中国癌症杂志 ›› 2020, Vol. 30 ›› Issue (1): 57-63.doi: 10.19401/j.cnki.1007-3639.2020.01.007

• 论著 • 上一篇    下一篇

JMJD3和Ki-67定量检测与乳腺浸润性导管癌分子分型及临床病理学特征的关系

徐小艳 1 ,王建君 1 ,王 慧 2 ,王 娜 1 ,刘 薇 3 ,杨金花 1   

  1. 1. 河南中医药大学人民医院(郑州人民医院)病理科,河南 郑州 450000 ;
    2. 河南中医药大学人民医院(郑州人民医院)院士工作站,河南 郑州 450000 ;
    3. 河南中医药大学人民医院(郑州人民医院)乳腺外科,河南 郑州 450000
  • 出版日期:2020-01-30 发布日期:2020-01-17
  • 通信作者: 杨金花 E-mail: jinhuay65@sina.com
  • 基金资助:
    河南省普通科技攻关计划(182102311189)。

Quantitative detection of JMJD3 and Ki-67 in invasive ductal carcinoma of breast and their relationship with molecular typing and clinicopathological features

XU Xiaoyan 1 , WANG Jianjun 1 , WANG Hui 2 , WANG Na 1 , LIU Wei 3 , YANG Jinhua 1   

  1. 1. Department of Pathology, People’s Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China; 2. Academy of Sciences Expert Workstation, People’s Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China; 3. Department of Breast Surgery, People’s Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China
  • Published:2020-01-30 Online:2020-01-17
  • Contact: YANG Jinhua E-mail: jinhuay65@sina.com

摘要: 背景与目的:对乳腺癌分子标志物的研究有助于乳腺癌患者的诊断及预后判断,探讨乳腺浸润性导管癌中JMJD3表达和Ki-67增殖指数与分子分型及临床病理学特征的关系。方法:采用免疫组织化学法检测河南中医药大学人民医院的57例正常乳腺组织、38例乳腺低级别导管内癌、52例乳腺高级别导管内癌及150例乳腺浸润性导管癌原发灶中JMJD3表达和Ki-67增殖指数,用图像分析软件对JMJD3表达和Ki-67增殖指数进行定量测试,分析JMJD3表达和Ki-67增殖指数与乳腺浸润性导管癌分子分型及临床病理学特征的关系。结果:JMJD3在正常乳腺组织、乳腺低级别导管内癌、乳腺高级别导管内癌和乳腺浸润性导管癌中表达依次降低,Ki-67增殖指数在上述组织中表达依次升高。JMJD3表达和Ki-67增殖指数与乳腺浸润性导管癌组织学分级、淋巴结转移状况、pTNM分期及分子亚型均有关(P<0.05)。受试者工作特征(receiver operating characteristic,ROC)曲线显示,JMJD3诊断阈值≤10.87,Ki-67诊断阈值≥8.08时,诊断乳腺癌的灵敏度和特异度均较高。Spearman相关分析显示,JMJD3表达与Ki-67增殖指数呈显著负相关(r P =0.984,P=0.000)。结论:JMJD3和Ki-67在乳腺癌发生、发展中扮演着重要角色。JMJD3表达与Ki-67增殖指数呈负相关,提示JMJD3的高表达能够抑制乳腺癌细胞的增殖,其具体分子生物学机制有待进一步深入研究。

关键词: 乳腺浸润性导管癌, JMJD3, Ki-67, 相关性, 分子亚型

Abstract: Background and purpose: The study of molecular markers for breast cancer is helpful to diagnosis of the disease and prediction of prognosis in breast cancer patients. The purpose of this study was to investigate the relationship between JMJD3 and Ki-67 and molecular typing and clinicopathological characteristics in invasive ductal carcinoma of breast. Methods: The levels of JMJD3 and Ki-67 were examined on tissues of 57 normal controls, 38 low-grade ductal carcinoma in situ, 52 high-grade ductal carcinoma in situ and 150 primary invasive ductal carcinoma of breast in People’s Hospital of Henan University of Chinese Medicine by immunohistochemical method. The levels of JMJD3 and Ki-67 were assessed quantitatively using Image-Pro Plus image analysis software, and their relationship with molecular subtypes and clinicopathological characteristics of breast cancer was analyzed. Results: Positive intensity of JMJD3 in normal control tissues, low-grade ductal carcinoma in situ, high-grade ductal carcinoma in situ and invasive ductal carcinoma of breast was decreased sequentially, whereas Ki-67 intensity was increased. The levels of JMJD3 and Ki-67 were positively correlated with the degree of histologic differentiation, lymph node metastasis status, TNM stage and molecular subtypes (P<0.05). The receiver operating characteristic (ROC) curve showed that the sensitivity and specificity of diagnosis of breast cancer were higher when the JMJD3 diagnostic threshold was less than 10.87 and the Ki-67 diagnostic threshold was more than 8.08. JMJD3 expression was negatively correlated with Ki-67 proliferation index (r P =-0.540, P=0.000). Conclusion: JMJD3 and Ki-67 play an important role in the development of breast cancer. High expression of JMJD3 inhibits proliferation of breast cancer cells, and the specific molecular biological mechanism needs further study.

Key words: Invasive ductal carcinoma of breast, JMJD3, Ki-67, Correlation, Molecular subtypes